Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Clarius Group LLC

Clarius Group LLC lowered its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 3.5% in the second quarter, Holdings Channel.com reports. The institutional investor owned 1,089 shares of the biopharmaceutical company’s stock after selling 40 shares during the quarter. Clarius Group LLC’s holdings in Regeneron Pharmaceuticals were worth $572,000 as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of the business. Vanguard Group Inc. grew its stake in Regeneron Pharmaceuticals by 1.3% during the 1st quarter. Vanguard Group Inc. now owns 9,407,891 shares of the biopharmaceutical company’s stock valued at $5,966,767,000 after purchasing an additional 121,545 shares in the last quarter. Price T Rowe Associates Inc. MD grew its stake in Regeneron Pharmaceuticals by 4.3% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 2,175,026 shares of the biopharmaceutical company’s stock valued at $1,379,467,000 after purchasing an additional 89,579 shares in the last quarter. Amundi grew its stake in Regeneron Pharmaceuticals by 3.4% during the 1st quarter. Amundi now owns 1,603,901 shares of the biopharmaceutical company’s stock valued at $979,794,000 after purchasing an additional 52,166 shares in the last quarter. Goldman Sachs Group Inc. grew its stake in Regeneron Pharmaceuticals by 18.0% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,143,093 shares of the biopharmaceutical company’s stock valued at $724,984,000 after purchasing an additional 174,056 shares in the last quarter. Finally, American Century Companies Inc. grew its stake in Regeneron Pharmaceuticals by 2.1% during the 1st quarter. American Century Companies Inc. now owns 722,467 shares of the biopharmaceutical company’s stock valued at $458,211,000 after purchasing an additional 14,921 shares in the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Analyst Upgrades and Downgrades

REGN has been the subject of a number of recent analyst reports. Sanford C. Bernstein raised their price objective on Regeneron Pharmaceuticals from $753.00 to $781.00 and gave the company an “outperform” rating in a research note on Wednesday, August 27th. Raymond James Financial raised Regeneron Pharmaceuticals to a “moderate buy” rating in a report on Tuesday, September 2nd. Rothschild & Co Redburn began coverage on Regeneron Pharmaceuticals in a report on Thursday, August 14th. They set a “buy” rating and a $890.00 target price on the stock. Royal Bank Of Canada increased their target price on Regeneron Pharmaceuticals from $688.00 to $695.00 and gave the stock a “sector perform” rating in a report on Monday, August 4th. Finally, Morgan Stanley reaffirmed an “overweight” rating and set a $761.00 target price (up previously from $754.00) on shares of Regeneron Pharmaceuticals in a report on Friday, August 1st. Three equities research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, seven have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $817.67.

Regeneron Pharmaceuticals Price Performance

Shares of REGN stock opened at $600.00 on Monday. Regeneron Pharmaceuticals, Inc. has a 1 year low of $476.49 and a 1 year high of $1,024.36. The stock has a market cap of $63.59 billion, a PE ratio of 15.12, a price-to-earnings-growth ratio of 1.92 and a beta of 0.31. The business’s fifty day moving average is $572.12 and its 200-day moving average is $566.55. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.72 and a current ratio of 4.60.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share (EPS) for the quarter, beating the consensus estimate of $8.43 by $4.46. Regeneron Pharmaceuticals had a return on equity of 15.06% and a net margin of 31.37%.The company had revenue of $3.68 billion for the quarter, compared to analysts’ expectations of $3.30 billion. During the same period last year, the firm earned $11.56 EPS. The firm’s revenue for the quarter was up 3.6% on a year-over-year basis. Equities analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Wednesday, September 3rd. Stockholders of record on Monday, August 18th were given a dividend of $0.88 per share. The ex-dividend date was Monday, August 18th. This represents a $3.52 annualized dividend and a dividend yield of 0.6%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is 8.87%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.